SCHEMBL9867435

SCHEMBL9867435

O=C(N/C(=N\CCSc1ccccc1)NCCCc1c[nH]cn1)c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 6/20 0.42
RAB9A P51151 6/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
RECQL P46063 1/20 0.42
HRH4 Q9H3N8 4/20 0.41
HRH2 P25021 4/20 0.41
HRH1 P35367 1/20 0.40
HRH3 Q9Y5N1 1/20 0.40
KMT2A Q03164 2/20 0.38
ALDH1A1 P00352 4/20 0.38
HDAC1 Q13547 1/20 0.37
NFKB1 P19838 2/20 0.37
NFKB2 Q00653 2/20 0.37
RELA Q04206 2/20 0.37
CYP1A2 P05177 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
HPGD P15428 1/20 0.36
CYP2C19 P33261 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9866763 1.00 NPC1 (0.42) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL10369046 0.95 HRH4 (0.42) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9866485 0.95 HRH4 (0.42) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9865721 0.94 HPGD (0.47) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9865207 0.94 NPC1 (0.37) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9865726 0.94 HPGD (0.47) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9867694 0.94 HRH2 (0.44) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9866766 0.93 HRH2 (0.49) NPC1RAB9ASMN1; SMN2RECQLHRH4
SCHEMBL9865750 0.90 RAB9A (0.43) NPC1RAB9ASMN1; SMN2HRH4HRH2
SCHEMBL9865876 0.89 HPGD (0.46) NPC1RAB9ASMN1; SMN2RECQLHRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5021431-A H-1 antagonist, h-2 agonist for treating hypertension, cardiac disease or arterial occlusion HEUMANN PHARMA GMBH & CO. (DE) 1991-06-04 US disclosed
EP-0199845-A1 Imidazolylalkylguanidin derivatives, process for their preparation and pharmaceutical compositions containing them HEUMANN PHARMA GMBH & CO (DE) 1986-11-05 EP disclosed